AIF重组质粒的构建、表达和功能的研究

目的构建人凋亡诱导因子(AIF)基因功能片段的真核表达载体pcDNA3.1( )AIF,并初步研究AIF在细胞凋亡中的作用。方法从人细胞中提取总RNA,RTPCR扩增AIF基因片段;克隆到pMD18T载体上,通过酶切和测序进行鉴定;将AIF基因片段插入pcDNA3.1( ),构建真核表达载体;电转化淋巴母细胞Raji细胞,观察AIF的表达水平和功能。结果成熟AIF蛋白分子在真核细胞中表达,并转移到细胞核中,诱导Caspase非依赖性细胞凋亡。结论成功构建了pcDNA3.1( )AIF真核表达载体,AIF在Caspase非依赖性细胞凋亡中发挥重要作用。     

米团花色素的提取及其稳定性研究

米团花色素是云南省某些地区居民使用的一种传统黄色天然食用色素.本研究表明,米团花色素在433 nm和326 nm处分别有一个较强吸收峰.稳定性实验表明:该色素对酸、热、光、氧化剂过氧化氢(不加热)、常见金属离子、食盐及食糖等稳定,但在碱性条件或亚硫酸钠存在时不太稳定.此外,加入过氧化氢后加热也会引起其吸光值的显著改变.初步确定米团花色素主要为胺类物质.在正常加工条件下,是一种较理想的天然食用色素.     

九节茶资源调查与开发前景

通过调查,华南部分地区,包括广东、广西及江西等地的九节茶资源非常丰富,极具开发前景.     

腹腔镜保留肾单位肾肿瘤切除术对肾细胞癌患者肾功能和预后的影响

目的：分析肾细胞癌患者接受腹腔镜保留肾单位肾肿瘤切除术治疗对其肾功能及预后的影响。方法：收集2017年1月至2022年3月重庆医科大学附属第一医院泌尿外科接诊的肾细胞癌患者182例作为研究对象,采取随机法将患者进行分组,一组应用腹腔镜根治性肾切除术进行治疗,共91例为对照组,另一组应用腹腔镜保留肾单位肾肿瘤切除术进行治疗,共91例为研究组,对比两组患者术后肾功能及预后效果差异性。结果：研究组患者术后住院时间（P=0.011）优于对照组,对照组患者手术期间出血量（P<0.001）及手术时间（P=0.019）优于研究组,差异均有统计学意义;研究组患者手术后24 h血清肌酐水平（P=0.013）低于对照组,差异有统计学意义;研究组患者术后认知功能（P=0.018）、躯体功能（P=0.021）、社会功能（P=0.025）、情绪功能（P=0.032）及总体生活质量（P=0.033）等各维度评分高于对照组,差异有统计学意义。结论：临床中为肾细胞癌患者提供腹腔镜保留肾单位肾肿瘤切除术进行治疗可以缓解对患者肾功能造成的影响,提升患者手术治疗后的生活质量水平。     

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

BackgroundHyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC), could be beneficial to both hyperphosphatemia and anemia.MethodsRelevant literature from PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials (CCRCT) and MEDLINE databases were searched up to 21 February 2022, in order to conduct a meta-analysis to investigate the efficacy, safety and economic benefits of ferric citrate treatment in CKD patients with hyperphosphatemia and anemia. The meta-analysis was conducted independently by two reviewers using the RevMan software (version 5.3).ResultsIn total, this study included 16 randomized clinical trials (RCT) involving 1754 participants. The meta-analysis showed that ferric citrate could significantly reduce the serum phosphorus in CKD patients compared to the placebo control groups (MD −1.76 mg/dL, 95% CI (−2.78, −0.75); p = 0.0007). In contrast, the difference between ferric citrate treatment and active controls, such as non-iron-based phosphate binders, sevelamer, calcium carbonate, lanthanum carbonate and sodium ferrous citrate, was not statistically significant (MD − 0.09 mg/dL, 95% CI (−0.35, 0.17); p = 0.51). However, ferric citrate could effectively improve hemoglobin levels when compared to the active drug (MD 0.43 g/dL, 95% CI (0.04, 0.82); p = 0.03) and placebo groups (MD 0.39 g/dL, 95% CI (0.04, 0.73); p = 0.03). According to eight studies, ferric citrate was found to be cost-effective treatment in comparison to control drugs. Most of the adverse events (AE) following ferric citrate treatment were mild at most.ConclusionCollectively, our review suggests that iron-based phosphate binder, ferric citrate is an effective and safe treatment option for CKD patients with hyperphosphatemia and anemia. More importantly, this alternative treatment may also less expensive. Nevertheless, more scientific studies are warranted to validate our findings.     

Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis

Atherosclerosis(AS)is the main pathological cause of coronary heart disease(CHD).Current clinical interventions including statin drugs can effectively reduce acute myocardial infarction and stroke to some extent,but residual risk remains high.The current clinical treatment regimens are relatively effective for early atherosclerotic plaques and can even reverse their progression.However,the effectiveness of these treatments for advanced AS is not ideal,and advanced atherosclerotic plaques—the pathological basis of residual risk—can still cause a recurrence of acute cardiovascular and cerebrovascular events.Recently,nanomedicine-based treatment strategies have been extensively used in antitumor therapy,and also shown great potential in anti-AS therapy.There are many microstructures in late-stage atherosclerotic plaques,such as neovascularization,micro-calcification,and cholesterol crystals,and these have become important foci for targeted nanomedicine delivery.The use of targeted nanoparticles has become an important strategy for the treatment of advanced AS to further reduce the residual risk of cardiovascular events.Furthermore,the feasibility and safety of nanotechnology in clinical treatment have been preliminarily confirmed.In this review,we summarize the application of nanomedicine delivery in the treatment of advanced AS and the clinical value of several promising nanodrugs.     

18F-FDG PET在原发性乳腺淋巴瘤诊疗中的应用进展

原发性乳腺淋巴瘤（PBL）是一种罕见的、原发于乳腺组织的恶性结外肿瘤,其临床表现常缺乏特异性,且病程进展较快,早期诊断有利于改善患者预后。 18F-氟脱氧葡萄糖（FDG）PET作为一种日趋成熟的分子影像技术,联合CT或MRI对PBL具有较高的诊断灵敏度和准确率,且在PBL的分期和疗效评价中具有重要价值。笔者就...     

单节段截骨治疗椎体形成不良型脊柱侧后凸畸形的疗效分析

目的：分析应用单节段截骨治疗椎体形成不良型脊柱侧后凸畸形（congenital kyphoscoliosis,CKS）的临床疗效。方法：回顾性分析2006年7月至2012年5月应用后路单节段截骨椎弓根钉内固定治疗19例椎体形成不良型CKS患者,平均19.2岁,其中9例行经椎弓根椎体截骨术（pedicle subtraction osteotomy,PSO）,10例行全椎体截除术（vertebra cloumn resection,VCR）。对比观察手术情况、影像学分析、疼痛视觉模拟评分（visual analogue scale,VAS）、美国脊髓损伤协会（American Spinal Injury Asso－ciation,ASIA）分级和并发症。结果：手术时间（302.1±43.2） min,术中出血（589.5±151.5） ml,平均融合节段6.0±1.5;术后侧凸角矫正率（79.7±9.2）%,局部后凸角矫正率（81.1±21.9）%,颈7垂线-骶骨中线距离（vertical line between the 7th vertebra and central sacra,C7-CSL）矫正率（82.7±12.5）%。上述指标在PSO组和VCR组间差异无统计学意义（P >0.05）。但术前局部后凸角VCR组62.2°±21.0°明显大于PSO组22.7°±22.0°,t=4.009,P=0.001。经过平均4.2年随访,所有患者脊柱侧凸角、局部后凸角及冠状面偏移未见明显进展,VAS改善（85.9±15.9）%,ASIA分级3例D均恢复至E。所有患者并发症发生率21.1%,1例硬脊膜损伤,2例单侧下肢麻木,1例慢性腰痛,随访期间所有患者植骨融合良好,无伤口感染、螺钉松动移位、内植入断裂发生。结论：一期后路单节段截骨椎弓根钉内固定治疗椎体形成不良型CKS安全可行,可获得良好的矫正效果,其中VCR术应用于脊柱矢状面矫形更有优势。     

基于TGF-β/smad信号通路探讨七方胃痛颗粒对人胃腺癌AGS细胞上皮间质转化过程的影响＊

目的 探究七方胃痛颗粒对转化生长因子-β1（TGF-β1）诱导人胃腺癌细胞AGS上皮间质转化（Epithelial-mesenchymal transition， EMT）过程的影响及其潜在分子机制。方法 为了探究七方胃痛颗粒对TGF-β1处理的AGS细胞增殖、迁移和侵袭的影响，实验分为四组：AGS细胞对照组，EMT空白模型组，中药血清组，TGF-β/smad通路抑制剂组，分别利用CCK8、细胞划痕实验和Transwell实验检测细胞增殖、迁移和侵袭能力。此外，通过免疫荧光检测EMT过程中相关蛋白（E-cadherin、N-cadherin、14-3-3ζ、Smad2和p-Smad2/3）的表达水平。结果 与AGS细胞对照组相比，TGF-β1诱导EMT过程，显著促进AGS细胞增殖、迁移和侵袭，下调了E-cadherin的表达，上调了N-cadherin、14-3-3ζ、Smad2和p-Smad2/3的表达；与EMT空白模型组相比，中药血清组、TGF-β/smad通路抑制剂组显著抑制了细胞增殖、迁移和侵袭，上调了E-cadherin的表达，降低了N-cadherin、14-3-3ζ、Smad2和p-Smad2/3的表达。结论 七方胃痛颗粒通过调控TGF-β/smad信号通路从而抑制人胃腺癌AGS细胞的EMT过程。     

通窍活血汤加减治疗偏头痛疗效观察

目的：观察通窍活血汤对瘀阻脑络型偏头痛的治疗效果。方法：选择９０例分为两组,治疗组５０例以通窍活血汤加减治疗,对照组４０例以尼莫地平片和西比灵胶囊治疗;两组治疗前、后均经ＴＣ２０２０超声经颅多谱勒诊断仪测定颅内主要动脉血流速度。结果：治疗组治愈３６例,显效１０例,无效４例,总有效率９２％;对照组治愈１７例,显效１０例,无效１３例,总有效率６７５％;两组总有效率经χ２检验有非常显著性差异（Ｐ＜００１）。治疗组颅内动脉平均血流速度治疗前、后比较有非常显著性差异（Ｐ＜００１）;两组治疗后比较各项指标也均有非常显著性差异（Ｐ＜００１）。结论：通窍活血汤是治疗瘀阻脑络型偏头痛的有效方药。